Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

[1]  Å. Sjöholm,et al.  Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor , 2010, Molecular and Cellular Endocrinology.

[2]  A. Baron,et al.  The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats , 2010, Cardiovascular diabetology.

[3]  E. Diamandis,et al.  Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. , 2010, Endocrinology.

[4]  S. N. Murthy,et al.  The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats , 2010, Diabetes & vascular disease research.

[5]  P. Yan,et al.  Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. , 2010, American journal of hypertension.

[6]  J. Holst,et al.  Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. , 2010, American journal of physiology. Heart and circulatory physiology.

[7]  B. Hoogwerf,et al.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study , 2010, Cardiovascular diabetology.

[8]  R. Henkelman,et al.  Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice , 2010, Diabetes.

[9]  J. Jensen,et al.  The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. , 2009, Pharmacological research.

[10]  R. Shannon,et al.  Glucagon‐like Peptide‐1 and Myocardial Protection: More than Glycemic Control , 2009, Clinical cardiology.

[11]  L. Blonde,et al.  Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone , 2009, Cardiovascular diabetology.

[12]  P. Doevendans,et al.  Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. , 2009, Journal of the American College of Cardiology.

[13]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[14]  L. Macconell,et al.  Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Clinical therapeutics.

[15]  D. Drucker,et al.  Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways , 2008, Circulation.

[16]  T. Engstrøm,et al.  Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart , 2008, Regulatory Peptides.

[17]  L. D. dos Santos,et al.  Determination of myocardial infarction size in rats by echocardiography and tetrazolium staining: correlation, agreements, and simplifications. , 2008, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[18]  R. Watson,et al.  GLUT4 translocation: the last 200 nanometers. , 2007, Cellular signalling.

[19]  C. Anderson,et al.  Biological activity of AC3174, a peptide analog of exendin-4 , 2007, Regulatory Peptides.

[20]  M. Mocanu,et al.  Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway , 2007, Cardiovascular Drugs and Therapy.

[21]  R. Shannon,et al.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[22]  O. Alfieri,et al.  A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. , 2006, Journal of the American College of Cardiology.

[23]  Dennis D. Kim,et al.  Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes , 2006, Diabetes, obesity & metabolism.

[24]  G. Radda,et al.  Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart. , 2006, Cardiovascular research.

[25]  Ting Zhao,et al.  Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  A. Young,et al.  Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures , 2006, International Journal of Obesity.

[27]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[28]  S. Gardiner,et al.  Mesenteric Vasoconstriction and Hindquarters Vasodilatation Accompany the Pressor Actions of Exendin-4 in Conscious Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[29]  K. Clarke,et al.  Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment , 2005, Circulation.

[30]  E. Ingelsson,et al.  Insulin resistance and risk of congestive heart failure. , 2005, JAMA.

[31]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[32]  M. Nauck,et al.  Glucagon-like peptide 1 and its derivatives in the treatment of diabetes , 2005, Regulatory Peptides.

[33]  K. Wyne,et al.  Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? , 2005, Diabetes & vascular disease research.

[34]  J. Corbett,et al.  Incretin hormones and insulin sensitivity , 2005, Trends in Endocrinology & Metabolism.

[35]  A. Baron,et al.  Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. , 2005, Endocrinology.

[36]  T. Hintze,et al.  Limited Exercise Capacity in Heterozygous Manganese Superoxide Dismutase Gene–Knockout Mice: Roles of Superoxide Anion and Nitric Oxide , 2005, Circulation.

[37]  V. Fonseca,et al.  The impact of antidiabetic therapies on cardiovascular disease , 2005, Current atherosclerosis reports.

[38]  M. Mocanu,et al.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. , 2005, Diabetes.

[39]  J. Gardin,et al.  American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[40]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.

[41]  H. Taegtmeyer.  Cardiac metabolism as a target for the treatment of heart failure. , 2004, Circulation.

[42]  D. Drucker,et al.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.

[43]  L. Rydén,et al.  Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure , 2004, Diabetes & vascular disease research.

[44]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[45]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[46]  B. Ludvik,et al.  Effects of dichloroacetate on exercise performance in healthy volunteers , 1993, Pflügers Archiv.

[47]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[48]  M. Heiman,et al.  Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. , 2004, Obesity research.

[49]  J. Knuuti,et al.  Insulin Signalling and Resistance in Patients with Chronic Heart Failure , 2003, The Journal of physiology.

[50]  R. Roman,et al.  Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats , 2003, Journal of hypertension.

[51]  Kieran Clarke,et al.  The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. , 2003, Cardiovascular research.

[52]  D. Drucker,et al.  Cardiac function in mice lacking the glucagon-like peptide-1 receptor. , 2003, Endocrinology.

[53]  L. Rydén,et al.  Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium , 2003, Peptides.

[54]  Mohit M. Jain,et al.  Cardiac-Specific Overexpression of GLUT1 Prevents the Development of Heart Failure Attributable to Pressure Overload in Mice , 2002, Circulation.

[55]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[56]  D. Yellon,et al.  Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling , 2001, Circulation research.

[57]  S. Sollott,et al.  Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes , 2001, Circulation research.

[58]  A. Young,et al.  Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1 , 2001 .

[59]  D. Drucker,et al.  Minireview: the glucagon-like peptides. , 2001, Endocrinology.

[60]  O. Carretero,et al.  Echocardiographic assessment of cardiac function in conscious and anesthetized mice. , 1999, American journal of physiology. Heart and circulatory physiology.

[61]  M. Schwaiger,et al.  Contribution of (cid:97) -Adrenergic and (cid:98) -Adrenergic Stimulation to Ischemia-Induced Glucose Transporter (GLUT) 4 and GLUT1 Translocation in the Isolated Perfused Rat Heart , 2022 .

[62]  M. Schwaiger,et al.  Contribution of alpha-adrenergic and beta-adrenergic stimulation to ischemia-induced glucose transporter (GLUT) 4 and GLUT1 translocation in the isolated perfused rat heart. , 1999, Circulation research.

[63]  C. Conti.  Cardiovascular diabetology. , 1999, Clinical cardiology.

[64]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[65]  P. Douglas,et al.  Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. , 1994, Circulation.

[66]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[67]  M. Pfeffer,et al.  Myocardial Infarct Size and Ventricular Function in Rats , 1979, Circulation research.

[68]  H. Selye,et al.  Simple Techniques for the Surgical Occlusion of Coronary Vessels in the Rat , 1960, Angiology.